(Q33275198)

25 July 2017

0 references

Meta-analysis: the efficacy of nootropic agent Cerebrolysin in the treatment of Alzheimer's disease (English)

1 reference

25 July 2017

0 references

1 reference

Z-H Wei

1

1 reference

25 July 2017

Q-B He

2

1 reference

25 July 2017

H Wang

3

1 reference

25 July 2017

B-H Su

4

1 reference

25 July 2017

H-Z Chen

5

1 reference

25 July 2017

publication date

23 February 2007

1 reference

Journal of Neural Transmission

25 July 2017

published in

1 reference

25 July 2017

volume

114

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

629-634

1 reference

A double-blind, placebo-controlled, multicenter study of Cerebrolysin for Alzheimer's disease

25 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS00702-007-0630-Y

Increased density of glutamate receptor subunit 1 due to Cerebrolysin treatment: an immunohistochemical study on aged rats.

21 January 2018

1 reference

12 December 2020

Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent.

1 reference

12 December 2020

The effects of nerve growth factor on spatial recent memory in aged rats persist after discontinuation of treatment.

1 reference

12 December 2020

A 24-week, double-blind, placebo-controlled study of three dosages of Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy

1 reference

12 December 2020

Sustained improvement of cognition and global function in patients with moderately severe Alzheimer's disease: a double-blind, placebo-controlled study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

Sustained improvements in patients with dementia of Alzheimer's type (DAT) 6 months after termination of Cerebrolysin therapy.

1 reference

12 December 2020

A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease.

1 reference

12 December 2020

Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT).

1 reference

12 December 2020

Meta-analysis: formulating, evaluating, combining, and reporting

1 reference

12 December 2020

Cerebrolysin decreases amyloid-beta production by regulating amyloid protein precursor maturation in a transgenic model of Alzheimer's disease.

1 reference

12 December 2020

Amplification of blood-brain barrier GLUT1 glucose transporter gene expression by brain-derived peptides

1 reference

12 December 2020

Amelioration of the cerebrovascular amyloidosis in a transgenic model of Alzheimer's disease with the neurotrophic compound cerebrolysin

1 reference

12 December 2020

Improved global function and activities of daily living in patients with AD: a placebo-controlled clinical study with the neurotrophic agent Cerebrolysin.

1 reference

12 December 2020

10.1007/S00702-007-0630-Y

Identifiers

DOI

1 reference

25 July 2017

1 reference